Quick Answer
VYNE Therapeutics Inc. reported Total Assets of $30.16 million for the year ending 2025.
- VYNE Therapeutics Inc. showed a decrease of -54.9% in Total Assets from 2024 to 2025.
- This data is from VYNE Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on February 27, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2018: $180.48 million | Q2 2018: $166.92 million | Q3 2018: $154.96 million | Q1 2019: $126.26 million | Q2 2019: $114.38 million | Q3 2019: $96.58 million | Q1 2020: $160.53 million | Q2 2020: $130.84 million | Q3 2020: $107.68 million | Q1 2021: $149.17 million | Q2 2021: $133.98 million | Q3 2021: $81.32 million | Q1 2022: $64.32 million | Q2 2022: $55.19 million | Q3 2022: $46.91 million | Q1 2023: $35.26 million | Q2 2023: $24.96 million | Q3 2023: $19.27 million | Q1 2024: $91.68 million | Q2 2024: $86.65 million | Q3 2024: $76.20 million | Q1 2025: $56.42 million | Q2 2025: $44.72 million.
- Over the full 10 years of available data (2016 to 2025), VYNE Therapeutics Inc.'s Total Assets has declined by 28.3%.
- Historical annual values: Fiscal year 2025: $30.16 million | Fiscal year 2024: $66.91 million | Fiscal year 2023: $97.69 million | Fiscal year 2022: $40.76 million | Fiscal year 2021: $67.05 million | Fiscal year 2020: $93.74 million | Fiscal year 2019: $81.16 million | Fiscal year 2018: $139.93 million | Fiscal year 2017: $66.87 million | Fiscal year 2016: $42.05 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: